D James Haddon1,2, Hannah E Wand1,2, Justin A Jarrell1,2, Robert F Spiera1,2, Paul J Utz1,2, Jessica K Gordon1,2, Lorinda S Chung3,4. 1. From the Division of Immunology and Rheumatology, Stanford University School of Medicine; Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford; Department of Rheumatology, Palo Alto VA Health Care System, Palo Alto, California; Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA. 2. D.J. Haddon, PhD, Research Associate, Immunology and Rheumatology, Division of Immunology and Rheumatology, Stanford University School of Medicine; H.E. Wand, BS, Genetic Counseling Candidate, Division of Immunology and Rheumatology, Stanford University School of Medicine; J.A. Jarrell, PhD Candidate, Immunology, Division of Immunology and Rheumatology, Stanford University School of Medicine; R.F. Spiera, MD, Professor of Clinical Medicine, Rheumatology and Director, Vasculitis and Scleroderma Program, Department of Rheumatology, Hospital for Special Surgery; P.J. Utz, MD, Professor of Medicine, Immunology and Rheumatology, Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine; J.K. Gordon, MD, Assistant Professor of Medicine, Rheumatology, Department of Rheumatology, Hospital for Special Surgery, New York; L.S. Chung, MD, MS, Associate Professor of Medicine, Immunology and Rheumatology, Division of Immunology and Rheumatology, Stanford University School of Medicine, and Department of Rheumatology, Palo Alto VA Health Care System. 3. From the Division of Immunology and Rheumatology, Stanford University School of Medicine; Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford; Department of Rheumatology, Palo Alto VA Health Care System, Palo Alto, California; Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA. shauwei@stanford.edu. 4. D.J. Haddon, PhD, Research Associate, Immunology and Rheumatology, Division of Immunology and Rheumatology, Stanford University School of Medicine; H.E. Wand, BS, Genetic Counseling Candidate, Division of Immunology and Rheumatology, Stanford University School of Medicine; J.A. Jarrell, PhD Candidate, Immunology, Division of Immunology and Rheumatology, Stanford University School of Medicine; R.F. Spiera, MD, Professor of Clinical Medicine, Rheumatology and Director, Vasculitis and Scleroderma Program, Department of Rheumatology, Hospital for Special Surgery; P.J. Utz, MD, Professor of Medicine, Immunology and Rheumatology, Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine; J.K. Gordon, MD, Assistant Professor of Medicine, Rheumatology, Department of Rheumatology, Hospital for Special Surgery, New York; L.S. Chung, MD, MS, Associate Professor of Medicine, Immunology and Rheumatology, Division of Immunology and Rheumatology, Stanford University School of Medicine, and Department of Rheumatology, Palo Alto VA Health Care System. shauwei@stanford.edu.
Abstract
OBJECTIVE: Imatinib has been investigated for the treatment of systemic sclerosis (SSc) because of its ability to inhibit the platelet-derived growth factor receptor and transforming growth factor-β signaling pathways, which have been implicated in SSc pathogenesis. In a 12-month open-label clinical trial assessing the safety and efficacy of imatinib in the treatment of diffuse cutaneous SSc (dcSSc), significant improvements in skin thickening were observed. Here, we report our analysis of sera collected during the clinical trial. METHODS: We measured the levels of 46 cytokines, chemokines, and growth factors in the sera of individuals with dcSSc using Luminex and ELISA. Autoantigen microarrays were used to measure immunoglobulin G reactivity to 28 autoantigens. Elastic net regularization was used to identify a signature that was predictive of clinical improvement (reduction in the modified Rodnan skin score ≥ 5) during treatment with imatinib. The signature was also tested using sera from a clinical trial of nilotinib, a tyrosine kinase inhibitor that is structurally related to imatinib, in dcSSc. RESULTS: The elastic net algorithm identified a signature, based on levels of CD40 ligand, chemokine (C-X-C motif) ligand 4 (CXCL4), and anti-PM/Scl-100, that was significantly higher in individuals who experienced clinical improvement than in those who did not (p = 0.0011). The signature was validated using samples from a clinical trial of nilotinib. CONCLUSION: Identification of patients with SSc with the greatest probability of benefit from treatment with imatinib has the potential to guide individualized treatment. Validation of the signature will require testing in randomized, placebo-controlled studies. Clinicaltrials.gov NCT00555581 and NCT01166139.
OBJECTIVE:Imatinib has been investigated for the treatment of systemic sclerosis (SSc) because of its ability to inhibit the platelet-derived growth factor receptor and transforming growth factor-β signaling pathways, which have been implicated in SSc pathogenesis. In a 12-month open-label clinical trial assessing the safety and efficacy of imatinib in the treatment of diffuse cutaneous SSc (dcSSc), significant improvements in skin thickening were observed. Here, we report our analysis of sera collected during the clinical trial. METHODS: We measured the levels of 46 cytokines, chemokines, and growth factors in the sera of individuals with dcSSc using Luminex and ELISA. Autoantigen microarrays were used to measure immunoglobulin G reactivity to 28 autoantigens. Elastic net regularization was used to identify a signature that was predictive of clinical improvement (reduction in the modified Rodnan skin score ≥ 5) during treatment with imatinib. The signature was also tested using sera from a clinical trial of nilotinib, a tyrosine kinase inhibitor that is structurally related to imatinib, in dcSSc. RESULTS: The elastic net algorithm identified a signature, based on levels of CD40 ligand, chemokine (C-X-C motif) ligand 4 (CXCL4), and anti-PM/Scl-100, that was significantly higher in individuals who experienced clinical improvement than in those who did not (p = 0.0011). The signature was validated using samples from a clinical trial of nilotinib. CONCLUSION: Identification of patients with SSc with the greatest probability of benefit from treatment with imatinib has the potential to guide individualized treatment. Validation of the signature will require testing in randomized, placebo-controlled studies. Clinicaltrials.gov NCT00555581 and NCT01166139.
Entities:
Keywords:
AUTOANTIBODIES; DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS; IMATINIB; NILOTINIB; PROTEIN MICROARRAYS
Authors: Janet Pope; Donna McBain; Lisa Petrlich; Sharon Watson; Louise Vanderhoek; Faye de Leon; Shannon Seney; Kelly Summers Journal: Arthritis Rheum Date: 2011-11
Authors: Dinesh Khanna; Rajeev Saggar; Maureen D Mayes; Fereidoun Abtin; Philip J Clements; Paul Maranian; Shervin Assassi; Rajan Saggar; Ram R Singh; Daniel E Furst Journal: Arthritis Rheum Date: 2011-11
Authors: S Prey; K Ezzedine; A Doussau; A-S Grandoulier; D Barcat; E Chatelus; E Diot; C Durant; E Hachulla; J-D de Korwin-Krokowski; E Kostrzewa; T Quemeneur; C Paul; T Schaeverbeke; J Seneschal; A Solanilla; A Sparsa; S Bouchet; S Lepreux; F-X Mahon; G Chene; A Taïeb Journal: Br J Dermatol Date: 2012-10-05 Impact factor: 9.302
Authors: D Khanna; D E Furst; R D Hays; G S Park; W K Wong; J R Seibold; M D Mayes; B White; F F Wigley; M Weisman; W Barr; L Moreland; T A Medsger; V D Steen; R W Martin; D Collier; A Weinstein; E V Lally; J Varga; S R Weiner; B Andrews; M Abeles; P J Clements Journal: Ann Rheum Dis Date: 2006-03-15 Impact factor: 19.103
Authors: Xiaochun Liu; Maureen D Mayes; Claudia Pedroza; Hilda T Draeger; Emilio B Gonzalez; Brock E Harper; John D Reveille; Shervin Assassi Journal: Arthritis Care Res (Hoboken) Date: 2013-08 Impact factor: 4.794
Authors: P Beirne; P Pantelidis; P Charles; A U Wells; D J Abraham; C P Denton; K I Welsh; P L Shah; R M du Bois; P Kelleher Journal: Eur Respir J Date: 2009-06-18 Impact factor: 16.671
Authors: Quan-Zhen Li; David R Karp; Jiexia Quan; Valerie K Branch; Jinchun Zhou; Yun Lian; Benjamin F Chong; Edward K Wakeland; Nancy J Olsen Journal: Arthritis Res Ther Date: 2011-03-02 Impact factor: 5.156
Authors: Marta Cossu; Lorenzo Beretta; Petra Mosterman; Maria J H de Hair; Timothy R D J Radstake Journal: Clin Rev Allergy Immunol Date: 2018-12 Impact factor: 8.667